A New Computer-Modelling Tool to Improve Psoriasis Management and Treatment Outcomes

At the 17th EADV Conference in Paris, LEO Pharma has unveiled a new weapon in its long-running campaign to improve psoriasis management and treatment outcomes. However, the weapon is not a new drug but a ground-breaking computer-modelling tool, designed to help those involved in the assessment, planning and provision of psoriasis treatment in primary care to balance optimum outcomes with the growing need for cost control.

Called 'Psoriasis and Me', the new computerised resource simulates the impact (over two years) of the use of a range of topical psoriasis therapies on patient outcomes and costs in a given primary care setting.

Co-developed in the UK by LEO Pharma and specialist health economics and outcomes research company Amygdala Ltd, 'Psoriasis and Me' has been piloted with English service providers for the past 11 months and is already endorsed by the UK’s National Association of Primary Care (NAPC).

The pilot has not only revealed the extent to which providers in England are unaware of the sizeable sums being spent on psoriasis but also the very real prospect of significant savings which could run into millions of pounds if replicated across the UK.

"Health economics is an increasingly important factor in service redesign but it is often seen as a cold discipline that works against patient needs; 'Psoriasis and Me' demonstrates that this doesn't have to be the case," said Peter Jackson, Commercial Development Manager for LEO UK.

"The programme has already shown that as a result of more effective prescribing for psoriasis in an English primary care population of, say, 250,000, yearly savings could be as high as £277,000. If you extrapolate that to the UK population as a whole (c60million), the potential annual saving could be as much as £66million."

The programme has also received extremely positive feedback from clinicians who have seen it in operation. Keith Freeman, a UK Consultant Dermatologist with dual responsibility for services in a primary care trust and a foundation hospital trust, sees the programme as a very welcome and valuable aid for local decision making. "The priority for service commissioners in treating psoriasis is to achieve the best pathways of care - to make sure that the right patients are being treated in the right place at the right time for the best possible outcomes. Treating effectively in primary care is better for the patient and also means secondary care resources can be focused on the most appropriate cases. Tools like this are the way forward to help clinicians review services, optimise care and keep better control of costs."

'Psoriasis and Me' works by comparing specific local data inputs - such as population size, waiting times for referrals to secondary care and the types and costs of treatments currently in use - to stored country-specific information and the Psoriasis Area and Severity Index (PASI 75). It then generates a report which calculates the optimum financial savings that could be made in a service redesign which would also improve patient outcomes using the most effective treatments.

"For decades, LEO Pharma has been at the forefront of challenging psoriasis," said Kristian Hart-Hansen, LEO Pharma's Manager of Corporate Pricing and Health Economics. "To date this has been with treatments but now that most countries insist on some form of Health Technology Assessment (HTA) to demonstrate cost effectiveness, we want to add value to the process. The idea for 'Psoriasis and Me' came from an HTA submission and, after the success of the UK pilot, its potential to reinforce our challenge to this life-affecting disease is very clear."

'Psoriasis and Me' is now under development for use in a number of Northern European countries and LEO Pharma plans to roll out the programme over the next two years.

About LEO Pharma
LEO Pharma is an independent research based company with headquarters in Ballerup, Denmark. LEO Pharma is 100% owned by the LEO Foundation and is a globally leading company within Dermatology and Critical Care. LEO Pharma has a strong focus on developing, manufacturing and marketing safe and efficacious drugs for treating psoriasis and other skin diseases as well as thromboembolic disorders. For further information, please visit www.leo-pharma.com.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...